a r t i c l e s
The quest for a cure for HIV infection was inspired by Timothy Ray Brown, an HIV-infected individual who, in the course of treatment for refractory leukemia with total-body irradiation and chemotherapy, also received two bone marrow transplants with CCR5-delta 32-mutated HIV-resistant cells. The combination of decreased HIV reservoirs and introduced resistant cells is thought to have cured not only his leukemia but also his HIV infection 1 . The success in Brown's case, despite being achieved with a highly toxic treatment, has galvanized the field to seek a functional cure (i.e., a prolonged period off ART without detectable plasma viremia) or HIV eradication through safer and more scalable approaches.
What are the cellular and anatomic compartments from which infection might rebound after ART and achieve a functional cure or eradication? To answer that question, we performed an extensive analysis of potential sources of viral rebound, using both established and next-generation in situ hybridization (ISH) technologies and quantitative image analysis. We paid particular attention to LTs in HIV and simian immunodeficiency virus (SIV) infections, in which CD4 + T cells in the gut and secondary LT have previously been shown to be the principal sites where most of the cells producing viral (v) RNA (vRNA + cells) are found in HIV-infected humans and SIV-infected macaques [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , and where there is a very large pool (more than 10 10 cells) of transcriptionally silent vDNA + cells in LTs 3 , some of which contain replication-competent proviruses.
Although previous characterizations of HIV-and SIV-infected tissues have clearly identified LT and the vDNA + and vRNA + cells therein as important anatomic sites and cellular sources of virus potentially capable of reigniting infection after treatment interruption [2] [3] [4] 7, 14, 16, 18, 19 , much of this work was done during the 1990s, before modern ART. Understanding of the extent to which current ART regimens affect virus burden in LT and other tissues is therefore incomplete. Moreover, recent evidence has indicated that even contemporary ART regimens that suppress viral replication and decrease plasma viremia to levels below the sensitivity of clinical laboratory assays achieve lower drug levels in LT than the fully suppressive drug levels in peripheral blood (PB) 5 . These lower tissue drug levels are correlated with incomplete suppression of viral replication in LT in some patients 19, 20 . There is also growing appreciation that the size of the pool of latently infected cells that may contribute to viral rebound after treatment interruption has been underestimated by as much as 70-fold (ref. 21 ). There are thus three good reasons to reexamine potential sources of rebound when ART is interrupted. a r t i c l e s 1 2 7 2 VOLUME 23 | NUMBER 11 | NOVEMBER 2017 nature medicine
To identify the sources of potential viral rebound, we conducted extensive analysis of necropsy tissues from rhesus macaques (RMs) infected with SIVmac251, SIVmac239, or RT-SHIV, by using the new easily performed techniques of DNAscope and RNAscope ISH to quantify vDNA + and vRNA + cells 22 ; a previously described ISH method using tyramide signal amplification (TSA) to score for virusproducing cells 23 ; and measurement of the intracellular concentrations of ART drugs and/or active metabolites to assess associations between suboptimal tissue drug concentrations and ongoing replication during ART. In HIV infection, we examined LT reservoirs in serial lymph node (LN) and gut biopsies obtained before and after at least 2 years of ART in HIV-infected people. We found that, in a nonhuman primate (NHP) model, in the absence of ART, >98% of detectable vRNA + and vDNA + cells were in LT. ART decreased the frequency of vRNA + cells, but, despite apparently clinically effective ART (plasma vRNA <50 copies/mL), vRNA + cells were detected in every organ system examined. In LN, in which tissue levels of ART drugs are substantially lower than those in PB, we found that virusproducing cells remained detectable, and we provide new estimates of the potential size of the pool of vDNA + cells in LTs with replicationcompetent proviruses. The persistence of virus-producing cells after ART and a large pool of vDNA + cells with the potential to become reactivated underscores the challenges of HIV eradication.
RESULTS

NHP studies
We analyzed brain, gut, heart, kidney, liver, lung, LN, and spleen tissues collected in necropsies of eight RMs infected with SIVmac251 (three untreated and five subjected to ART) and housed at Advanced Bioscience Laboratories. The three untreated SIVmac251-infected animals were euthanized and necropsied at 14, 43, or 90 d postinfection (dpi). The remaining five SIVmac251-infected animals were euthanized and necropsied after 20-22 weeks of treatment with raltegravir, darunavir (DRV), ritonavir (RTV), emtricitabine (FTC), and tenofovir (TFV) starting at 56 dpi (Supplementary Fig. 1a) . We also analyzed LN from 11 SIVmac239-infected RMs housed at the US National Institutes of Health (NIH) on suppressive ART regimens (described in the methods section and previous publications 22, 24, 25 ; Supplementary Fig. 1b,c) ; tissues from four untreated juvenile RMs infected with reverse transcriptase-SIV expressing HIV-1 envelope (RT-SHIV) and housed at the California National Primate Research Center (CNPRC), euthanized and necropsied at 19, 24, 41, or 69 weeks after infection; and tissues from four RT-SHIV-infected juvenile RMs housed at the CNPRC, after a minimum of 26 weeks of ART with a combination of efavirenz, FTC, and TFV 26 (Supplementary Fig. 1d) . We assessed the tissue virus burden in a total of 27 RMs infected with three distinct simian AIDS viruses.
Reservoir measurements by ISH
We used ISH technologies and quantitative image analysis to define tissue reservoirs in SIV/SHIV and HIV infections on the basis of numbers of vDNA + , vRNA + , and virus-producing cells. These cellular measurements thus defined reservoirs in a different way from PCR and RT-PCR analysis of nucleic acids extracted from homogenized whole tissues, in which there is ambiguity in attributing the number of copies of vDNA or vRNA to either a large number of cells with a few viral copies or to a small number of cells with a large number of viral copies. We used four methods of ISH: (i) 35 2, 3 but with greater speed, convenience and higher spatial resolution of the vDNA signal within infected cells. We compared the frequency of vRNA + and vDNA + cell/g LT to measurements of vRNA and vDNA by qRT-PCR and qPCR, and found excellent agreement (R 2 = 0.89 and P < 0.0001 for RNA and R 2 = 0.73 and P < 0.0001 for DNA; Supplementary  Fig. 2 ). The agreement with similar recently published results 22 provided further justification for this approach to quantifying viral reservoirs on a cellular basis in situ.
SIV RNA + cells are mainly in lymphoid tissues
We quantitatively characterized cellular tissue reservoirs in untreated SIV infection in the brain, heart, kidney, liver, lung, spleen, LNs (axillary, colonic, inguinal, and mesenteric), and multiple sites in the gut (duodenum, jejunum, ileum, ascending and transverse colon, and rectum) (representative images of SIV in situ hybridization from multiple tissues through two complementary approaches in Supplementary  Fig. 3 ). We analyzed serial 4-µm sections of formalin-fixed, paraffin-embedded tissues, evaluating every fifth section in a total of at least five sections to provide analysis through ≥80 µm of each tissue. The frequency of SIV RNA + cells was determined in each section and converted to the frequency per g on the basis of the measured area of the section, nominal thickness, and previously determined density of fixed tissue of ~1 g/cm (refs. 3,16) . For example, the frequency of vRNA + cells/µm 2 area × 4 µm thick = vRNA + cells/µm 3 × 10 12 µm 3 /cm 3 × 1 g/cm 3 = vRNA + cells per g tissue.
The density of vRNA + cells was highest in LT, but vRNA + cells were detected in every organ, including the heart, liver, and kidney, and the central nervous system. To estimate the total virus burden for different tissues, we assumed that each organ contributes vRNA + cells to the total population of vRNA + cells in an amount proportional to the frequency of vRNA + cells measured by ISH and the total mass of these organs. In the RMs studied at peak viremia, for example, the mass of the heart was approximately 38.3 g, and the frequency of vRNA + cells was 7.54 × 10 3 cells/g; thus, the total number of infected cells in this organ was accordingly estimated at ~2.89 × 10 5 cells (Supplementary Table 1 ). The combined mass of lymph nodes for this animal was estimated to be 78 g (~1% of total body mass). With a mean frequency of ~8.73 × 10 5 vRNA + cells/g, the total population of vRNA + cells in LNs was estimated at 7.68 × 10 7 cells, approximately 2 log 10 higher than that found in the heart. In the gut, we measured ~5.57 × 10 5 vRNA + and vDNA + cell populations are established in LT reservoirs in early infection We investigated differences in the frequency of viral nucleic acidpositive cells on the basis of anatomic site and duration of untreated SIVmac251 infection in four LNs (axillary, colonic, inguinal, and mesenteric) and from multiple sites in the gut (duodenum, jejunum, ileum, ascending colon, transverse colon, and rectum) in the acute (14 dpi), early (43 dpi), and later chronic stages (90 dpi) of infection. In the LN and gut, vRNA + cells were detected in early infection and varied by only approximately 0.5 log (Fig. 2a,b) , and we found remarkable consistency among LNs located in different anatomic locations. The estimated frequency of vDNA + cells in LT in the SIVmac251-infected animals, assessed with SIV DNAscope (Fig. 2c,d and Supplementary Fig. 4 ), also showed that substantial pools of vDNA + cells were established early and maintained at high levels in the chronic stages of infection in RMs. Table 2a ) and poor penetration of drugs into the brain. In the RT-SHIV-infected animals, 26 weeks of ART decreased the number of vRNA + cells by ~3 to 4 log 10 in all LT, but by only approximately twofold in the brain (Fig. 3b) . The greater decreases seen in the RT-SHIV-infected animals compared with SIVinfected animals may reflect the relative effectiveness of the different ART regimens against the respective target viruses, distinct differences in viral replication capacity in RMs, differences in tissue concentrations of ART, or Env-specific immune responses. We have previously shown in HIV-infected humans that the intracellular concentrations of antiretroviral drugs (ARVs) in LT can be significantly less than the concentrations in peripheral blood mononuclear cells (PBMCs) and well below the optimal concentration for viral suppression 5 . We measured intracellular concentrations of ARVs in PBMCs and cells of the LN, ileum (gut-associated lymphoid tissue (GALT)) and rectal-associated mucosal tissue (RALT) from six of the animals described above and similarly found lower ART concentrations in LT than in blood (Fig. 4) . The median ratios for TFV-diphosphate (TFV-DP, an active phosphorylated form of the drug) were 0.84 for LN/PBMCs, 0.41 for GALT/PBMCs, and 0.84 for RALT/PBMCs. The median ratios for FTC-triphosphate (FTC-TP) were 0.26 for LN/PBMCs, 0.32 for GALT/PBMCs, and 0.32 for RALT/PBMs. The median RALT/PBMC ratio for DRV was 15; however, DRV was not quantifiable in LN or GALT samples. Thus, the concentrations of the ARVs were not equivalent to those in peripheral blood in any of the studied compartments, with the exception of DRV a r t i c l e s in RALT (summary of intracellular concentration of ARVs for all drugs studied in Supplementary Table 3) . These results support the hypothesis that comparatively lower ARV concentrations in different tissues may contribute to incomplete suppression of viral replication in those tissues. With the exception of the heart tissues, vRNA + cells were detectable in every animal on ART, even though all had plasma viral loads <50 copies/mL (the limit of detection of the assay used). The highest numbers of vRNA + cells during ART were mainly in LTs (LN, spleen, and GALT) and the lung. Because detection of vRNA + cells signifies transcription and not necessarily virus production, we used ISH/TSA amplification with an enzyme-linked immunofluorescence technique (ELF97) to detect virus-producing cells through light microscopy 23 , to show that vRNA + cells also produced virus during ART. We measured the frequency of vRNA + cells with RNAscope and the frequency of cells producing virions with TSA/ELF97 in 20 subjacent sections from two of the SIVmac251-infected animals on suppressive ART for >6 months (Fig. 5) . There was good agreement between the two measurements (Supplementary Table 4) , a result consistent with the conclusion that most vRNA + cells detected in LN were producing virions.
We used DNAscope to assess the effects of ART on the frequency of vDNA + cells in 11 SIVmac239-infected animals that had been treated for a mean of 30 weeks (range 25-35 weeks) beginning at 4 weeks postinfection (wpi) (Fig. 3c and Supplementary Fig. 4 ).
Before ART, the mean frequency of vDNA + cells was ~1 × 10 7 cells/g LT. ART decreased the mean frequency of vDNA + cells/g by ~1.7 log 10 to ~3.5 × 10 5 cells/g LT. Thus, there was a very large residual reservoir of vDNA + cells during ART, the implications of which are discussed below.
HIV RNA + and DNA + cells in LT To compare residual virus levels in LT in SIV infection with those in HIV infection of humans, we analyzed LN and rectal samples collected before ART and after at least 2 years of ART from a cohort of 20 people in Kampala, Uganda. These individuals had advanced infection when ART was begun, in accordance with treatment guidelines in Uganda at the time when tissues were obtained. The average age of this cohort at entry was 32 years, and 50% were women. The mean CD4 + T cell count at the beginning of the study was 174 cells/mm 3 (range 30-309 cells/mm 3 ), and the mean plasma HIV viral load was 8.1 × 10 4 copies/mL (range 7.4 × 10 2 to 9.1 × 10 5 copies/mL) (individual changes in CD4 and plasma viral loads over time for a subset of 14 individuals followed longitudinally in Supplementary Figs. 5  and 6, respectively) .
On the basis of preliminary analyses in which we found that clade B riboprobes detected fewer vRNA + cells than did riboprobes for the prevalent clades A and D in Uganda (data not shown), we designed RNAscope and DNAscope probes specific to clades A and D for this study. With these probes, we determined an average frequency of vRNA + cells in the LN and rectum before ART of ~9.4 × 10 4 cells/g (6.3 × 10 3 to 3.5 × 10 5 cells/g) and ~2.5 × 10 5 cells/g (2.3 × 10 4 to 9.6 × 10 5 cells/g), respectively (Fig. 6a) , a result in reasonable agreement with previous estimates of ~5 × 10 4 /g in LNs of HIV-infected patients in the United States, with a mean CD4 + T cell count of 400 cells/µl (ref. 16 ). However, this value was more than tenfold lower than that observed in the SIVmac251-infected RMs necropsied at 90 dpi.
To determine the size of the vDNA + cell population before ART in relation to vRNA + cells (as an estimate of cells with transcriptionally competent proviruses in these snapshots), we performed DNAscope and RNAscope in LN and rectum specimens. Before ART, the mean frequency of vDNA + cells in LN was ~6.2 × 10 7 vDNA + cells/g LT (range 8.3 × 10 6 to 1.3 × 10 8 ) (Fig. 6b) , and thus the ratio of vRNA + cells to vDNA + cells was ~0.002, in good agreement with the ratios of 1:100 to 1:400 determined in previous studies using in situ PCR and ISH 2 .
ART had a significant effect on the LT reservoir in individuals who had been treated for >2 years (range 2-6 years) and had undetectable plasma viral loads (<40 copies/mL in the first 12 months of the study and then <20 copies/mL). The mean frequency of vDNA + cells declined by ~3 log, to ~2.7 × 10 5 cells/g (range 1.2 × 10 5 to 4.5 × 10 5 cells/g; P = 0.0237, analysis of variance (ANOVA)). In gut tissues, however, we did not observe a significant decrease in the size of the vDNA + -cell reservoir (Fig. 6c): before ART, the frequency of vDNA + cells was 
DISCUSSION
Using contemporary ISH methodologies to analyze tissue virus burdens as populations of infected cells, we confirmed the paramount importance of the LT reservoir before and during ART. These technologies also notably revealed that, during ART, vRNA + and virusproducing cells persist in tissues with plasma viremia of fewer than 50 copies/mL. Thus, our findings suggest that tissue assessments will be needed to fully determine the effectiveness of interventions designed to cure HIV infection.
In the NHP models in which we were able to comprehensively analyze key organ systems in a way that would not be possible in HIVinfected humans, ~99.6% of the SIV RNA + cells were found in LTs (LNs, gut, spleen, and lung). Thus, there is now compelling additional evidence supporting the conclusion that lymphoid organs are the principal tissue sites of virus production 7 . In the heart, liver, and kidney, the frequencies of vRNA + cells were very low, but we did find vRNA + cells in the brain (cortex) at a frequency of ~2.3 × 10 4 cells/g, and the frequency was comparable or higher in animals on ART, in agreement with a potentially important role of the brain as a site of viral persistence that may not be as amenable as peripheral tissues to viral suppression by ART, at least with the ARVs used in the present study 27, 28 .
In both SIV-infected RMs and HIV-infected people, ART suppressed viral replication, as evidenced by plasma vRNA measurements, but we readily detected vRNA + and virus-producing cells in tissues, albeit at lower frequencies than those in untreated animals. This evidence of continued low-level virus production despite ostensibly suppressive ART was correlated, particularly in the gut, with the lower relative concentrations of ARVs in tissues compared with PBMCs documented in these studies. Notably, our results are consistent with the conclusions from studies of HIV infection indicating that suboptimal tissue levels of ARVs in some treated infected individuals may not fully suppress virus production in tissues 5, 20 . In the Ugandan cohort, other factors such as tissue fibrosis, persistent gastrointestinal-tract damage and associated inflammation and greater CD4 + T cell depletion in advanced stages of infection at the time at which ART was initiated [29] [30] [31] [32] [33] may also have contributed to ongoing infection by further lowering drug levels and impairing containment of infection by the damaged immune system.
The presence of vRNA + cells in tissues during ART does not distinguish between low levels of ongoing virus production and reactivation of latently infected cells. What we can conclude from the estimated quasi-steady-state whole-body burden of 7 million vRNA + cells in LT snapshots in people on suppressive ART for >2 years is that either or both reservoirs are large immediate sources of virus that can reignite infection after treatment interruption. This conclusion is supported by the rapid multifocal rebound observed in LT with genetically diverse viruses with treatment interruption 19 in HIV-infected people on ART for an average of 14.6 years, and by the estimates determined in this study of the size of the pool of latently infected cells containing replication-competent and inducible proviruses. We found a frequency of vDNA + cells maintained in the LT reservoir at levels of ~10 5 vDNA + cells/g despite ART in both SIV and HIV infections. If, as recent estimates have suggested 21 , only ~5% of vDNA + cells have replication-competent and inducible proviruses, the total-body burden of latently infected cells with potentially inducible replication-competent proviruses would be ~4 × 10 8 cells. This estimate is in excellent agreement with measurements by Bruner et al., whose sequence analysis has suggested that a population of ~1.2 × 10 7 resting memory cells in PBMCs contain replicationcompetent provirus 34 . Given that fewer than 5% of resting memory cells are in peripheral blood, the frequency of vDNA + cells in LTs with replication-competent provirus would be on the order of ~2.4 × 10 8 cells. Thus, two independent methods converge on similar estimates of a very large potentially inducible reservoir in patients on current ART regimens.
Both ongoing low-level virus production due to lower concentrations of ARVs in LTs and reactivation of latently infected cells provide potential sources of virus that may rapidly reignite infection 4.78 µm 4.78 µm Figure 5 Virus-producing cells in two SIV-infected RMs during ART, detected by ISH/TSA. At left, the long arrow points to two virus-producing cells; the short arrow points to a cluster of four productively infected cells. At right, the arrow points to two productively infected cells. Yellow, virus particles; blue, cell nuclei. Multiphoton images were obtained at z steps of 0.1 µm and subsequently filtered to decrease the intracellular viral RNA staining and make virus particles visible. The sizes of virions depend on the plane of focus; larger virions are in focus.
Lymph node Rectum a r t i c l e s after treatment interruption. It will be important in future studies to develop and evaluate cure strategies that effectively target each source. For ongoing virus production, fully suppressive ARTs are needed for LT and other tissue sites. For the latently infected inducible population, strategies with significantly greater efficacy than that afforded by current latency-reversal agents, coupled with effective means to eliminate the reactivated cells, are also needed.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
Study procedures. At screening, peripheral blood was obtained to determine CD4 T cell counts and plasma HIV RNA levels. Just before ART initiation, all participants had an excisional inguinal lymph node biopsy, after which they were started on an ART regimen consisting of two nucleoside reverse transcriptase inhibitors (NRTI) and one non-NRTI, per the Ugandan national HIV-treatment guidelines. Subsequent CD4 T cell counts and HIV RNA levels were measured every 6 months to monitor treatment response. LN and rectal biopsies were repeated at 12, 24, and 36 months of follow-up.
Clinical and laboratory analysis (NHP)
. Tissues used in the described NHP studies were obtained from preexisting tissue banks or were part of additional approved studies. As such, no formal sample-size estimates were made before study design. No randomization was used to select animals for the study, and the inclusion/exclusion criteria are described below. The investigators were not blinded to the groups to which animals belonged or to the infection history or treatment regimen and duration.
Animals and SIV infection. The RMs of Indian origin (Macaca mulatta) used for SIV infection in these studies were mature male and female animals that The experimental conditions and ART regimens used for the 11 RMs housed at the National Cancer Institute were as previously described for five RMs (DCCN, DCHV, DCT3, DCEG, and DCJB) that received 26-32 weeks of ART beginning at 4 wpi and six RMs (DCLJ, DCT2, DCEA, DC1G, DCCP, and DCEW) that received a different regimen also begun at 4 wpi, for 31-32 weeks (refs. 22,24,25) . Lymph nodes were collected by surgical extraction before (4 wpi) and 26-32 weeks after the initiation of ART (30-40 wpi) and immediately fixed in freshly prepared neutral buffered 4% paraformaldehyde for 24h at room temperature. After fixation for 24h, the fixative was replaced with 80% ethanol, and tissues were paraffin embedded as previously described 25 . Stocks of RT-SHIV were prepared as described previously 26 . The RT-SHIV used had the T-to-C substitution at position 8 of the SIV tRNA-primer-binding site, which is necessary for efficient replication of RT-SHIV in vivo. Juvenile RMs 7 to 10 months of age (~2.0 to 3.1 kg) were used in the RT-SHIV study, as described by North et al. 26 . Efavirenz (200 mg per day) was given in food. The NRTIs PMPA and FTC were administered subcutaneously, with a regimen of 16 mg per kg body weight once daily for FTC and 30 mg per kg body weight once daily for PMPA. The dose of PMPA was decreased to 15 mg/kg per day after 20 weeks of treatment to limit potential long-term renal toxicity associated with prolonged administration at the higher dose.
Animals and RT
Analysis of CD4 T cell counts. For RMs, EDTA-treated whole blood was stained with monoclonal antibodies to CD3, CD4, and CD8 and analyzed with a BD FACSCalibur Flow Cytometer (BD Biosciences). Cell counts were determined with BD Trucount tubes according to the manufacturer′s instructions (BD Biosciences).
For humans, blood CD4 cell counts were measured at the same time points by flow cytometry with a FACSCount system (Becton Dickinson).
Quantification of plasma viral RNA load. For RMs, plasma isolated from EDTA-treated blood of SIVmac251-infected RMs was clarified by centrifugation at 2,300g for 3 min. The clarified plasma (0.1 mL) was then lysed directly in lysis buffer (bioMerieux). Alternatively, a higher volume of plasma (0.5 to 1 mL) was centrifuged to pellet virus by ultracentrifugation at 49,100g for 60 min, and the pellet was lysed in lysis buffer. The viral RNA load in the lysed samples was quantified with a real-time NASBA assay, as previously described 35 . Plasma SIVmac239/251 viral loads were determined as previously described, with an assay threshold of 30 copies/mL (refs. 24,25) . Plasma isolated from the blood of RT-SHIV-infected challenged macaques was analyzed with previously described methods 26 whose lower limit of detection was 5 copies/mL.
For humans, the plasma HIV viral load was measured with the COBAS Ampliprep/COBAS TaqMan 96 (Roche) platform, with a linearity range of 20-10,000,000 copies/mL, or the Abbott m2000 platform, with a linearity range of 40-10,000,000 copies/mL. The Abbott platform was used in the first 12 months of the study, and the Roche platform was used for all subsequent measurements. Both platforms were registered in an external quality-assurance program provided by the American Pathologists and Virology Quality Assurance from Rush University Medical Center.
Procedures for initial tissue management. At the time of biopsy, each LN was dissected into two pieces. One piece was transferred to 4% paraformaldehyde for 4-6 h, then washed in 80% ethanol and embedded in paraffin and subsequently sectioned in 4-ìm sections for ISH analysis.
In situ hybridization. These methods have been previously described. Briefly, for the radiolabeled and RNA/DNAscope techniques, a total of three to five 4-µm sections separated by 20 µm were analyzed by one of three ISH methods. For ISH/TSA/ELF, 10-µm sections were used.
Radiolabeled ( 35 S) in situ methods. Sections were hybridized at 45 °C overnight with a 35 S-labeled riboprobe and 0.5 mM aurintricarboxylic acid in the hybridization mix, with previously described methods 16 . After extensive washing and RNase treatment, tissue sections were dehydrated, coated in emulsion and exposed at 4 °C for 7-14 d.
ISH/TSA/ELF. These methods have been previously described 23, 36 . Briefly, sections were hybridized to digoxigenin-labeled HIV-specific antisense riboprobes with 0.5 mM aurintricarboxylic acid to decrease background. After hybridization, tissues were incubated with anti-digoxigenin antibody conjugated with HRP, extensively washed, and then incubated with biotinyl tyramine to amplify signals. The amplification step was repeated three times to detect virus particles. Tissues were then treated with streptavidin-alkaline phosphatase, and RNA signals were visualized with fluorescent ELF97 alkaline phosphatase substrate.
RNAscope/DNAscope. The antisense (for the detection of vRNA) and sense (for the detection of vDNA) SIV and HIV probes covered ~4.5 kb of the genome and were designed to bind sequences in gag, pol, vif, vpx (for SIV), vpr, tat, rev, vpu (for HIV), env, and nef, as previously described 22 .
Quantitative image analysis. Photographic images were captured, and the frequencies of vRNA + or vDNA + cells were measured and expressed as the total per unit area. These methods have been extensively reviewed 14, 18, 37 .
Quantification of antiretroviral-drug concentrations. Intracellular concentrations of TFV-DP, FTC-TP, DRV, and RTV were quantified from lysed cellular matrix from PBMCs and MNCs obtained from biopsy samples of the LN, ileum (GALT), and rectum (RALT), through previously described methods 5, 38 . Final sample extracts were quantified with a liquid chromatography-triple-quadrupole mass spectrometry system consisting of a Shimadzu Nexera ultra-highperformance liquid chromatograph attached to an AB Sciex 5500 QTrap mass spectrometer. Quality-control sample interbatch coefficients of variance for the TFV-DP and FTC-TP and the DRV and RTV methods were 3.84-7.67% and 1.1-7.4%, respectively. Absolute mean relative errors to the theoretical target quality-control samples were <5.6% for TFV-DP and FTC-TP and <8.1% for DRV and RTV. The batch acceptance criterion was derived according to the Food and Drug Administration Guidance for Industry on Bioanalytical Method Validation 39 . The results from intracellular analyses are expressed in femtomoles per million cells. The relative penetration of the ARVs into the LN, GALT, and RALT was assessed as a ratio of concentrations to those in PBMCs.
Statistical analysis. Data presented from individual animals to describe the frequency of vRNA or vDNA + cells are expressed as the total number of cells per g tissue for that organ in that animal (for example, Figs. 2 and 3) . Analyses of differences between tissue sites, or before and during ART, were made by comparing the means of the two groups with ANOVA (for example, Fig. 6 ).
Data availability. All data are available from the authors upon reasonable request. A Life Sciences Reporting Summary for this paper is available.
